Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Schmerz ; 33(5): 437-442, 2019 Oct.
Article in German | MEDLINE | ID: mdl-31531729

ABSTRACT

BACKGROUND: On March 10th 2017, the law amending narcotic and other regulations was expanded, thereby allowing physicians, irrespective of their specialization, to prescribe cannabis-derived medicines as magistral formulas or proprietary medicinal products at the expense of the German statutory health insurance (GKV). First prescription requires approval from the respective health insurance, which in turn commissions the Medical Advisory Board of the Statutory Health Insurance Funds (MDK) to prepare a medico-legal report. OBJECTIVES: Since § 31 Para. 6 of the German Social Code, Book V (SGB V) came into effect, a multitude of imponderables have been reported regarding reimbursement. Based on the experience of the MDK Nord, problems within the fields of patients, physicians and cannabis-derived medicines are illustrated. MATERIAL AND METHODS: Considering current literature, a retrospective review was conducted including approximately 2200 applications for reimbursement received in 2018 from patients residing in Hamburg and Schleswig-Holstein. RESULTS: A relevant problem within the field of patients resulted from the lack of a specific definition of the term "severe (chronic) disease". Although this term is mentioned several times in SGB V, it is not put into concrete terms. Circumstances like multimorbidity are not taken into account. Another problem consisted in an irreproducible anticipation of treatment with cannabis-derived medicines. Within the field of physicians, a major problem was caused by missing, fragmentary or inconsistent information regarding disease and/or therapy. Hence, initially, almost one-third of all applications could not be appraised. Amongst various cannabis-derived medicines, dried flowers were found to be the most problematic regarding doses and effective levels. Notably, a marked increase in numbers of applications for reimbursement of therapy with pure cannabidiol was noted. DISCUSSION: Numerous problems reported elsewhere and relating to prescription of cannabis-derived medicines were also observed by the MDK Nord. Many prescriptions reflected an uncertainty regarding therapeutic use of cannabis-derived medicines. Thus, one should consider restricting the prescription of cannabis-derived medicines to selected specialists. It should be noted that, in individual cases, e.g., patients suffering from neuropathic pain, treatment with cannabis-derived medicines seems to be a reasonable therapeutic option taking into account the risks and benefits.


Subject(s)
Cannabis , Chronic Pain , Financial Management , Insurance, Health, Reimbursement , Chronic Pain/drug therapy , Financial Management/standards , Financial Management/statistics & numerical data , Germany , Humans , Insurance, Health/economics , Insurance, Health/statistics & numerical data , Insurance, Health, Reimbursement/statistics & numerical data , Medical Marijuana/economics , Medical Marijuana/therapeutic use , Retrospective Studies
2.
Stud Health Technol Inform ; 228: 783-7, 2016.
Article in English | MEDLINE | ID: mdl-27577493

ABSTRACT

Each patient in outpatient treatment is assigned per quarter and corresponding physician to a case group that is strongly related to the morbidity (Morbidity Related Group, MRG). MRG is defined by the drug group on a four character level in the international anatomic-therapeutic-chemical (ATC) classification with the largest costs as an indicator for the severity of the drug treatment. Using severity levels we get a risk adjustment with respect to age and polypharmacy as an indicator for multimorbidity and treatment intensity. By application of MRG groups we generate a patient type classification in relation to physicians and a distance structure of the medical disciplines.


Subject(s)
Diagnosis-Related Groups , Outpatients/classification , Pharmaceutical Preparations/classification , Ambulatory Care , Humans , Morbidity , Physicians
3.
Endocrinology ; 153(3): 1103-15, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22253423

ABSTRACT

In both cell culture experiments and in vivo studies, a number of angiotensin II type 1 (AT(1)) receptor antagonists activated the peroxisome proliferator-activated receptor-γ (PPARγ). This mechanism has been discussed to be, at least in part, responsible for the improvement in glucose metabolism observed in animal studies and clinical trials. To investigate whether the PPARγ-dependent mechanism may represent a valid target for chronic therapy, spontaneously hypertensive rats (SHR) were fed either with a cafeteria diet (CD) or standard chow. CD-fed SHR were simultaneously treated with either telmisartan (TEL; 8 mg/kg(body weight)· d) or candesartan (CAND; 10 mg/kg(body weight)· d) for 3 months because TEL, but not CAND, has been demonstrated to be a strong activator of PPARγ. After 3 months, chow- and CD-fed controls were hypertensive, whereas TEL and CAND treatment resulted in normalized blood pressures in SHR. Body weight and the amount of abdominal fat (determined by magnetic resonance imaging) were higher in CD- than in chow-fed SHR. After TEL or CAND, body weight, abdominal fat quantity, and adipocyte size returned to normal. In glucose tolerance tests, the glucose responses were comparable in the TEL- and CAND-treated SHR and obese controls, whereas the insulin response was almost halved by AT(1) blockade. Expression of PPARγ target genes aP2, FAT CD36, FASn, and PEPCK remained unaltered at the protein level in visceral fat after TEL and CAND compared with the CD-fed controls. Because the expression of examined PPARγ target genes was not affected, we concluded that improved insulin sensitivity after long-term treatment with AT(1) blockers was not related to a PPARγ-dependent mechanism.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/pharmacology , Gene Expression Regulation , Insulin/metabolism , PPAR gamma/metabolism , Adipocytes/cytology , Animals , Benzimidazoles/pharmacology , Benzoates/pharmacology , Biphenyl Compounds , Body Weight , Glucose Tolerance Test , Hemodynamics , Hypothalamus/metabolism , Insulin Resistance , Male , Models, Biological , Obesity/metabolism , Rats , Rats, Inbred SHR , Telmisartan , Tetrazoles/pharmacology
4.
Ann Nutr Metab ; 56(2): 127-42, 2010.
Article in English | MEDLINE | ID: mdl-20134158

ABSTRACT

BACKGROUND/AIMS: The metabolic syndrome (MS) has become an epidemiological problem in Western countries. We developed a diet-induced obese rat model that mimics all the symptoms of MS in humans, but whose insulin resistance, hyperphagia and hyperleptinemia are caused by nutrition rather than genetic modifications. METHODS: Spontaneously hypertensive rats (SHR) were allowed for 12 weeks to choose between a cafeteria diet (CD, 20.3 kJ/g) and standard rat chow (11.7 kJ/g). Controls received rat chow. RESULTS: Body weight (BW) exceeded control levels when SHR were fed with CD. The increase in BW was attributed to enhanced energy intake. The abundance of abdominal fat as well as the plasma levels of leptin and triglycerides increased concomitant with glucose, insulin and C-peptide. This prediabetic condition was further confirmed by a markedly increased insulin response following glucose challenge and by impaired glucose utilization after insulin tolerance tests. CONCLUSION: Increases in food intake and BW despite hyperleptinemia indicate leptin resistance following CD feeding. CD-fed SHR feature leptin and insulin resistance, hypertension and obesity, thus mimicking the situation of MS patients. As such, our model is more suitable than the genetically modified rat models used to study human MS.


Subject(s)
Hyperphagia/complications , Metabolic Syndrome/etiology , Obesity/etiology , Abdominal Fat , Animals , Biomarkers/blood , Blood Glucose , Blood Pressure , Body Weight , C-Peptide/blood , Diet/adverse effects , Diet/methods , Disease Models, Animal , Energy Intake , Heart Rate , Hyperphagia/blood , Insulin/blood , Insulin Resistance , Leptin/blood , Male , Metabolic Syndrome/blood , Obesity/blood , Rats , Rats, Inbred SHR , Rats, Sprague-Dawley , Triglycerides/blood
5.
Biochem Biophys Res Commun ; 390(1): 165-70, 2009 Dec 04.
Article in English | MEDLINE | ID: mdl-19799857

ABSTRACT

Lipin functions in mammalian phospholipid biosynthesis through its phosphatidate phosphohydrolase 1 (PAP(1)) activity. Here, we studied cardiac PAP(1) activity and lipin expression ex vivo in 8-month-old Zucker diabetic fatty (ZDF) rats and humans with type 2 diabetes mellitus undergoing open heart surgery for coronary bypass grafting. Compared to non-diabetic littermates (ZDF-fa/+), left ventricular PAP(1) activity was 29% lower in diabetic ZDF-fa/fa rats. Left ventricular PAP(1) activities were 2.1-fold (ZDF-fa/fa) and 3.6-fold (ZDF-fa/+) higher than the respective atrial activities, indicating marked differences in cardiac distribution of PAP(1). PAP(1) activity was highly related with cardiac lipin-1 and lipin-3 mRNA expression in ZDF rats (r=0.99 and 0.96). Consistent with the findings in experimental animals, human atrial tissue displayed PAP(1) activity that was 33% lower in those having diabetes than in non-diabetic controls. Accordingly, atrial lipin-1 and lipin-3 mRNA expression in diabetic patients was 50% and 59% lower as in non-diabetic patients, respectively. Insulin therapy increased both PAP(1) activity and lipin mRNA expression in diabetic patients. We conclude that suppression of cardiac PAP(1) activity/lipin expression may contribute to metabolic dysfunction of the diabetic heart.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Myocardium/metabolism , Nuclear Proteins/biosynthesis , Phosphatidate Phosphatase/metabolism , Animals , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/therapy , Heart Atria/enzymology , Heart Atria/metabolism , Heart Ventricles/enzymology , Heart Ventricles/metabolism , Humans , Insulin/therapeutic use , Male , Myocardium/enzymology , Nuclear Proteins/genetics , Pancreatitis-Associated Proteins , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Rats , Rats, Zucker
6.
Cardiovasc Res ; 78(1): 108-15, 2008 Apr 01.
Article in English | MEDLINE | ID: mdl-18096574

ABSTRACT

AIMS: Since mitogen-activated protein kinases (MAPKs) were found to be implicated in the signalling of ischaemic preconditioning (IPC), we tested the hypothesis of a contribution of these protein kinases to remote preconditioning (RPC). METHODS AND RESULTS: To determine the role of p38, ERK1/2, and JNK1/2 MAPKs in mediating cardiac protection, an in vivo model of myocardial infarction was applied in male Wistar rats. RPC or IPC was induced by occlusion of the superior mesenteric artery or the left coronary artery, respectively. Infarct size (IS) was determined based on 2,3,5-triphenyltetrazolium chloride staining. Phosphorylation of the various MAPKs was analysed by immunoblotting in samples of the small intestine and myocardium obtained after IPC or RPC procedures. The MAPK inhibitors SB203580 (p38), PD98059 (ERK1/2), and SP600125 (JNK1/2) were administered to assess the potential significance of MAPK signalling in RPC. Both preconditioning stimuli decreased myocardial IS significantly after a lethal period of ischaemia. Each of the applied MAPK inhibitors was capable of abrogating the RPC-induced cardioprotection. Western blot analysis of myocardial samples revealed an increase in phosphorylated amounts of ERK1/2 and JNK1 after IPC, whereas phosphorylation of p38 protein was decreased significantly. Likewise, RPC resulted in a considerable increase in phosphorylation of ERK1/2 and JNK1/2 proteins in the small intestine, whereas it did not alter the MAPK phosphorylation state in the myocardium. CONCLUSION: All investigated MAPK pathways appear to be involved in RPC-induced cardioprotection; however, they do not contribute to the alterations that define the preconditioned state of the myocardium prior to the infarction.


Subject(s)
Intestine, Small/enzymology , Ischemic Preconditioning, Myocardial/methods , MAP Kinase Signaling System , Mitogen-Activated Protein Kinases/metabolism , Myocardial Infarction/therapy , Myocardial Reperfusion Injury/prevention & control , Myocardium/enzymology , Animals , Blotting, Western , Hemodynamics , Intestine, Small/drug effects , MAP Kinase Signaling System/drug effects , Male , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Mitogen-Activated Protein Kinase 8/metabolism , Mitogen-Activated Protein Kinase 9/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Myocardial Infarction/enzymology , Myocardial Infarction/pathology , Myocardial Reperfusion Injury/enzymology , Myocardial Reperfusion Injury/pathology , Myocardium/pathology , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Rats , Rats, Wistar , p38 Mitogen-Activated Protein Kinases/metabolism
7.
Biochem Biophys Res Commun ; 352(2): 437-43, 2007 Jan 12.
Article in English | MEDLINE | ID: mdl-17125738

ABSTRACT

Hypoxia-inducible factors (HIFs) are key mediators of cellular adaptation to hypoxia, but also respond to non-hypoxic stimuli. To clarify involvement in metabolic disturbances, HIFs were characterised in rats subjected to insulin-induced hypoglycaemia or cellular glucoprivation provoked by 2-deoxy-D-glucose (2-DG). Using real-time qPCR, organ-specific expression of HIF-1alpha, -2alpha, -3alpha, -1beta, and of the target gene GLUT-1 was determined. Distribution of HIF-3alpha proteins was examined by immunohistochemistry. Both, insulin and 2-DG resulted in a widespread increase in HIF-3alpha mRNA. HIF-2alpha mRNA increased in lung and heart after 2-DG only, whereas other HIFs remained unaffected. A pronounced increase of protein levels in cerebral cortex was observed for HIF-3alpha. Functional significance of HIF induction was reflected in enhancement of GLUT-1 mRNA. Transcriptional up-regulation of HIF-3alpha represents a typical response to in vivo hypoglycaemia and glucoprivation. These data suggest an involvement of the HIF system in metabolic derangements as for instance caused by diabetes.


Subject(s)
Deoxyglucose/administration & dosage , Hippocampus/metabolism , Insulin/administration & dosage , Transcription Factors/metabolism , Animals , Apoptosis Regulatory Proteins , Cells, Cultured , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Hippocampus/drug effects , Hypoxia/metabolism , Male , Mice , Organ Specificity , Rats , Rats, Wistar , Repressor Proteins , Tissue Distribution
8.
Regul Pept ; 127(1-3): 217-24, 2005 Apr 15.
Article in English | MEDLINE | ID: mdl-15680490

ABSTRACT

Excitation of sensory nerves and activation of myocardial protein kinase C (PKC) epsilon contribute to the transduction of remote preconditioning (RPC) to the heart. Since calcitonin gene related peptide (CGRP) is an important mediator of sensory neurons we tried to delineate whether CGRP a) protects the heart from ischemic injury, b) is involved in cardioprotection after RPC, and c) leads to an activation of myocardial PKCepsilon. RPC was achieved by brief mesenteric artery occlusion followed by reperfusion. Myocardial infarct size (IS) was measured by TTC staining after temporary coronary artery occlusion (CAO) in rats. CGRP plasma levels were determined by radioimmunoassay and PKCepsilon was measured by quantitative immunoblotting. CGRP infusion reduced infarct size by 57%, an action that was abolished after co-treatment with the PKC inhibitor chelerythrine. RPC significantly increased CGRP plasma levels, reduced infarct size, and activated myocardial PKCepsilon. Infarct size reduction was abolished and PKCepsilon activation was significantly attenuated by CGRP(8-37), a specific CGRP receptor antagonist. Ganglion blockade with hexamethonium did not influence CGRP release by RPC but abolished CGRP mediated myocardial PKCepsilon activation. In conclusion, CGRP protects the heart from ischemic injury and is involved in RPC, presumably by activating myocardial PKCepsilon.


Subject(s)
Calcitonin Gene-Related Peptide/pharmacology , Cardiotonic Agents/pharmacology , Heart/drug effects , Ischemic Preconditioning, Myocardial , Animals , Blood Pressure/drug effects , Blood Pressure/physiology , Calcitonin Gene-Related Peptide/blood , Cardiotonic Agents/metabolism , Dose-Response Relationship, Drug , Enzyme Activation , Male , Myocardial Infarction/pathology , Myocardial Ischemia , Neurons, Afferent/metabolism , Protein Kinase C/metabolism , Protein Kinase C-epsilon , Random Allocation , Rats , Rats, Wistar
9.
Free Radic Biol Med ; 38(1): 117-24, 2005 Jan 01.
Article in English | MEDLINE | ID: mdl-15589380

ABSTRACT

Iron chelation by deferoxamine (DFO) blocks the Fenton reaction, but also inhibits prolyl hydroxylases and thereby activates certain hypoxia-inducible transcription factors (HIFs) that trigger cellular adaptation to hypoxia. Because both mechanisms may alleviate tissue damage in ischemia and reperfusion, we tried to differentiate their contribution to DFO-induced cardioprotection. Myocardial ischemia and reperfusion were induced in anesthetized Wistar rats. Infarct size was related to the ischemic area. Myocardial mRNA expression was determined by real-time PCR. Radical reactivity was probed in myocardial tissue slices with the redox-sensitive dye CM-H(2)DCFDA. Single ip applications of DFO (200 mg/kg) administered 2 h to 3 days before infarction reduced infarct size from 55 +/- 7% to 22-26%. Protection was abolished by the radical scavenger N-(2-mercaptopropionyl)glycine and the protein kinase C inhibitor chelerythrine when either was given 30 min before DFO, whereas subsequent application was ineffective. DFO did not alter the expression of various HIF target genes, whereas mRNAs of HIF-independent genes, aldose reductase and glucose transporter-4, were increased in infarcted myocardium 2 days after DFO treatment. Enhancement of superoxide activity by DFO could be demonstrated in vitro. Acute and prolonged myocardial preconditioning is triggered by DFO in response to accumulation of oxygen radicals and activation of protein kinase C.


Subject(s)
Deferoxamine/pharmacology , Glycine/analogs & derivatives , Iron Chelating Agents/pharmacology , Ischemic Preconditioning, Myocardial , Myocardial Reperfusion Injury/pathology , Superoxides/metabolism , Aldehyde Reductase/metabolism , Alkaloids , Animals , Aryl Hydrocarbon Receptor Nuclear Translocator , Basic Helix-Loop-Helix Transcription Factors , Benzophenanthridines , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Glucose Transporter Type 4 , Glycine/pharmacology , Hypoxia-Inducible Factor 1, alpha Subunit , Male , Monosaccharide Transport Proteins/metabolism , Muscle Proteins/metabolism , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardial Reperfusion Injury/metabolism , Phenanthridines/pharmacology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Rats , Rats, Wistar , Receptors, Aryl Hydrocarbon/genetics , Receptors, Aryl Hydrocarbon/metabolism , Sulfhydryl Compounds/pharmacology , Trans-Activators/genetics , Trans-Activators/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism
10.
FASEB J ; 17(11): 1541-3, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12824304

ABSTRACT

The role of the hypoxia-inducible factor (HIF) subunits 1alpha and 1beta in cellular response to hypoxia is well established, whereas little is known about HIF-2alpha and HIF-3alpha with respect to organ distribution and transcriptional regulation by hypoxia. We investigated mRNA levels of all HIF subunits and of their target genes erythropoietin (EPO) and glucose-transporter 1 (GLUT1) in rats undergoing systemic hypoxia for 30 or 120 min by quantitative real-time RT-PCR. In normoxia, persistently high mRNA levels of all HIF subunits were detected in cerebral cortex, hippocampus, and lung; the heart contained the lowest amounts. Hypoxia did not affect mRNA levels of HIF-1alpha, -1beta, and -2alpha. HIF-3alpha mRNA levels increased in all organs examined after 2 h of hypoxia. A significant rise of EPO and GLUT1 mRNA levels occurred in cortex, heart, liver, and kidney after 2 h of hypoxia, indicating activation of the HIF system. Protein levels of all HIF subunits, determined in brain and lung by immunoblotting, showed a marked increase corresponding to the duration of hypoxia. Our results suggest that induction at the transcriptional level is a unique feature of HIF-3alpha, which therefore may represent a rapidly reacting component of the HIF system in protection against hypoxic damage.


Subject(s)
Transcription Factors/biosynthesis , Animals , Apoptosis Regulatory Proteins , Basic Helix-Loop-Helix Transcription Factors , Cell Hypoxia , Erythropoietin/genetics , Erythropoietin/metabolism , Gene Expression Regulation , Glucose Transporter Type 1 , Hypoxia-Inducible Factor 1, alpha Subunit , Kinetics , Male , Models, Genetic , Monosaccharide Transport Proteins/genetics , Monosaccharide Transport Proteins/metabolism , Organ Specificity , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Repressor Proteins , Trans-Activators/biosynthesis , Trans-Activators/genetics , Transcription Factors/genetics
11.
J Cardiovasc Pharmacol ; 41(3): 474-80, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12605027

ABSTRACT

In addition to their lipid-lowering properties, statins improve endothelial function by increasing the activity of endothelial nitric oxide synthase (eNOS). It was hypothesized that, by this mechanism, statins protect the myocardium from ischemia/reperfusion injury in normocholesterolemic animals. Rats were pretreated for 1 week with either cerivastatin (0.3 mg/kg/d) or placebo. Anesthetized animals underwent 30 minutes of coronary artery occlusion (CAO) followed by 180 minutes of reperfusion. In a separate set of experiments, the NOS inhibitor l-NAME (15 mg/kg; N -nitro-l-arginine methyl ester) was administered 15 minutes before CAO. Cerivastatin decreased infarct size by 49% (P < 0.05) without reducing plasma cholesterol levels. Cerivastatin increased myocardial eNOS mRNA and NOS activity and by 52% and 58% (P < 0.05), respectively. Cardioprotection and upregulation of eNOS activity evoked by cerivastatin were not observed in rats cotreated with l-NAME. These results show that statins reduce the extent of myocardial necrosis in normocholesterolemic rats after acute ischemia/reperfusion injury by increasing myocardial eNOS activity. Therefore, statins may protect the heart not only by reducing the incidence of ischemic events, but also by limiting cell damage during acute myocardial infarction.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Myocardial Infarction/drug therapy , Myocardial Infarction/enzymology , Nitric Oxide Synthase/physiology , Animals , Enzyme Activation/drug effects , Enzyme Activation/physiology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Male , Myocardial Infarction/pathology , Nitric Oxide Synthase Type III , Rats , Rats, Wistar
12.
Cardiovasc Res ; 55(3): 583-9, 2002 Aug 15.
Article in English | MEDLINE | ID: mdl-12160956

ABSTRACT

OBJECTIVE: Myocardial protection can be achieved by brief ischemia-reperfusion of remote organs, a phenomenon described as remote preconditioning (RPC). Since the intracellular mechanisms of RPC are not known, we tested the hypothesis that RPC might activate myocardial PKCepsilon, an essential mediator of classical ischemic preconditioning. Furthermore, we tried to delineate the mechanisms by which RPC is transduced to the heart with respect to the possible contribution of kinins and neuronal reflexes. METHODS: Anesthetized rats were randomised to undergo either 30 min of waiting (controls) or RPC (brief mesenteric artery occlusion followed by reperfusion) in the absence or presence of chelerythrine (5 mg kg(-1)), a specific PKC inhibitor. Myocardial infarct size was measured by TTC staining after 30 min of coronary artery occlusion followed by 150 min of reperfusion. In separate sets of experiments RPC was performed with or without pretreatment with HOE140, a selective B(2)-antagonist or hexamethonium was used to explore the influence of ganglion blockade on RPC. Translocation of PKCepsilon from cytosol to the particulate fraction was measured by quantitative immunoblotting. RESULTS: RPC significantly reduced infarct size which was completely blocked by the PKC inhibitor. RPC shifted the ratio between cytosolic and particulate PKCepsilon, an indicator for PKC-activation, from 0.95+/-0.06 in controls to 0.41+/-0.09 (P<0.05), and this effect was abolished by HOE140. Activation of PKCepsilon could not be achieved after pretreatment with HEX (0.69+/-0.06 in HEX vs. 0.78+/-0.06 in HEX+RPC). CONCLUSIONS: RPC activates myocardial PKCepsilon through a neuronal and bradykinin-dependent pathway. We assume that activation of PKCepsilon is an important step in cardioprotection induced by remote preconditioning.


Subject(s)
Bradykinin/analogs & derivatives , Intestines/blood supply , Ischemic Preconditioning/methods , Isoenzymes/metabolism , Myocardial Infarction/prevention & control , Phenanthridines/pharmacology , Protein Kinase C/antagonists & inhibitors , Adrenergic beta-Antagonists/pharmacology , Alkaloids , Animals , Benzophenanthridines , Bradykinin/pharmacology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Ganglionic Blockers/pharmacology , Hexamethonium/pharmacology , Ischemic Preconditioning, Myocardial , Male , Myocardial Infarction/pathology , Myocardium/pathology , Random Allocation , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...